The Clinical Efficacy of Intravesical Botox Injections When Combined With HoLEP Surgery in Patients With Benign Prostatic Hyperplasia and Overactive Bladder

Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in men. Almost 90% of men in their 70s report lower urinary tract symptoms related to BPH. These symptoms carry a significant negative impact on the patients' quality of life.
Despite the wide availability of surgical offerings to relieve bladder outlet obstruction such as transurethral resection of the prostate (TURP), Holmium Laser Enucleation of the Prostate (HoLEP), and prostatectomy, many patients still suffer from persistent LUTS after undergoing these. A study describing postoperative outcomes following HoLEP revealed that patients with severe lower urinary tract symptoms, storage-positive sub-score, and high maximum urinary flow rate before the surgery were affected by a rebound of mainly storage symptoms 6-8 weeks after HoLEP and prolonged recovery from LUTS with 7.4% of them presenting for persistent urge complaints.
Optimizing the management approach for these patients has been limited by lack of high level evidence-based recommendations and expert consensus. Intravesical botox injections are well-established therapeutic options for several urinary disorders. The current practice offers intravesical botox injections to patients who suffer from persistent urinary symptoms few months after their BPH procedure. This study aims to evaluate if giving botox injections at the time of the HoLEP surgery would yield a better outcome than performing the two procedures separately at different times (few months apart).
The concomitant use of botox injection during bladder de-obstructing procedures has been previously studied in TURP and have showed a significant reduction of incontinence episodes and OAB symptoms in the group that were treated with botox injections after 36 weeks post TURP. This data may suggest promising potential of this intervention in managing persistent OAB symptoms in patients with BOO. However, the efficacy of combining HoLEP and bladder Botox injections has not been systematically studied and evaluated.
The aim of this study is to evaluate the effect of intravesical Botox injections on lower urinary tract symptoms (LUTS) when administered during HoLEP surgery in patients with bladder outlet obstruction (BOO) and overactive bladder symptoms (OAB). The investigators are interested in comparing the postoperative outcome in terms of recovery and symptom relief in patients who performed HoLEP surgery with bladder Botox injections versus those who performed HoLEP surgery only at 2 weeks,1 month, 3 months, and 6 months postoperatively.
The investigators hypothesize that administering bladder botox injections during HoLEP surgery is a combination treatment that will result in faster and more potent symptom relief compared to patients who received only a HoLEP surgery for their obstructive and irritative symptoms.

开始日期2026-06-01

申办/合作机构

University Hospitals Cleveland Medical Center

NCT07220382

/ Recruiting临床4期IIT

PREoperative Targeted OnabotulinumtoXina Injection for Abdominal Wall Reconstruction: A Randomized, Double-Blind, Placebo-Controlled Trial

This study is for adults who need open surgery to repair a very large abdominal (ventral) hernia. This study tests whether a one-time, image-guided injection of a medicine commonly known as "BOTOX®" (onabotulinumtoxinA) into the side abdominal muscles 3-7 weeks before surgery helps surgeons close the abdominal wall fully at the end of the operation. Closing the muscle and tissue layers ("primary fascial closure") is linked to fewer problems after surgery and better quality of life.
Participants will be randomly assigned (like a coin flip) to receive either the BOTOX® medicine or a saltwater (placebo) injection. Neither patients nor the care team will know which one was given. All participants will still have their planned hernia repair in the standard way that we repair patients who are not part of the study. The study will track whether the abdomen can be closed without leaving a gap, and investigators will also look at recovery, complications, time in the ICU or on a ventilator, length of stay, pain, and quality-of-life scores. Most information will be collected during participants' hospital stay, but the investigators will continue to see how participants are doing up to 2 years after surgery. Short phone check-ins will occur before surgery, and after surgery follow-up happens around 30 days, 90 days, 1 year, and 2 years.
Possible risks from the injection include temporary muscle weakness, trouble swallowing or breathing, pain or infection at the injection site, and (if CT is used for guidance) a small amount of radiation exposure. Surgery itself carries the usual risks (pain, bleeding, wound problems). Benefits are not guaranteed, but the injection may make closure easier and recovery smoother. About 188 people will take part at Cleveland Clinic.

开始日期2025-11-03

申办/合作机构

The Cleveland Clinic Foundation

NCT07160699

/ Not yet recruitingN/AIIT

To Evaluate the Effectiveness of an Interprofessional, Collaborative Approach to the Treatment of Spasticity Comprising Botulinum Toxin & Non-pharmacological Post-injection Therapy. A Study Protocol of a Multi-Centred N-of-1 Series

Many people with neurological conditions will experience spasticity, a nonvolitional and uncontrollable tightening and/or spasm of muscles. This can impact the person's functioning and independence in everyday tasks and can contribute to contractures. Spasticity and contracture develop and affect each person differently. Treatment is provided by a multi-disciplinary team (MDT), working collaboratively to offer the best combination of medications (including botulinum neurotoxin (BoNT)) and non-pharmacological interventions. There are a wide range of therapy interventions available. Each person's treatment plan is uniquely tailored to them, their individual presentation, and their treatment goals. Evidencing the effectiveness of spasticity and contracture treatment has been difficult. The manifestation and treatment of spasticity is never the same between patients. The experience of the condition and the perceived and observable effectiveness of treatment are unique to the individual. Treatment is most effective when MDT's work together to combine the most appropriate medications and therapies in a treatment plan individualised to the person and their presentation. Understanding how expert teams formulate spasticity treatment and how effectively their expertise influences spasticity outcomes could help inform practice.
The purpose of this multicenter, case study series is to evaluate the effectiveness of two conceptually similar, specialised MDT approaches for the treatment of patients with spasticity in two cross-national neurorehabilitation facilities.
The goal of this study is to investigate the effectiveness of interprofessional treatments of non-drug interventions in combination with botulinum toxin injections in patients who suffer from spasticity.
The main goals of the study are to evaluate:
1. Describe and evaluate the types of botulinum toxin and therapy treatment choices expert MDTs make when treating people with spasticity.
2. Evaluate whether a MDT approach to the assessment and treatment of spasticity using BoNT and non-pharmacological interventions is effective at achieving patient goals.
3. Evaluate whether a MDT approach to the assessment and treatment of spasticity using BoNT and non-pharmacological interventions, improves impairment and activity/participation outcomes using commonly used clinical outcome measures.
There will be no comparison group. The N-of-1, ABC study design allows participants to serve as their own controls.
Participants will undergo assessements to describe their goals and severity of spasticity:
* Goal Attainment Scale light
* ArmA & SQoL-6D
* LegA
* Modified Ashworth Scale
* Modifies Tardieu Scale
* Muscle Strength according to MRC
* Pain Measurement (NRS, VAS or other)

开始日期2025-10-01

申办/合作机构-

100 项与 A型肉毒毒素相关的临床结果

登录后查看更多信息

100 项与 A型肉毒毒素相关的转化医学

登录后查看更多信息

100 项与 A型肉毒毒素相关的专利（医药）

登录后查看更多信息

5,339

项与 A型肉毒毒素相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Systematic review of pharmacotherapy for atypical facial pain: evaluation of pain reduction, depression, anxiety and quality of life

Review

作者: Alshammari, Sattam S. ; Alassaf, Hind M. ; Alqarni, Ali A. ; Abed, Hassan H. ; Shaikh, Sameer ; Alshammari, Abdullah F. ; Alkurdi, Khlood A. ; Alshammary, Freah L. ; Madfa, Ahmed A.

BACKGROUND/PURPOSE:

Atypical facial pain (AFP) is a chronic condition characterized by persistent facial pain without clear clinical signs, making diagnosis and treatment difficult. Common pharmacological treatments include antidepressants, anticonvulsants and neuromodulators, but their effectiveness remains uncertain, necessitating a systematic review to guide clinical practice.

MATERIALS AND METHODS:

Following PRISMA 2020 guidelines, randomized controlled trials (RCTs) evaluating pharmacological treatments for AFP in adults were included. A comprehensive search of five databases without date restrictions was performed. Data on pain reduction, quality of life, and adverse events were extracted. The Cochrane Risk of Bias (RoB 2.0) tool assessed bias, and evidence quality was evaluated using the Critical Appraisal Skills Programme tool.

RESULTS:

Out of 196 studies identified, 10 RCTs met the inclusion criteria. Pharmacological responses varied significantly across studies. Antidepressants such as dothiepin and clomipramine demonstrated significant pain reduction, whereas venlafaxine showed limited efficacy. However, onabotulinum toxin A and sumatriptan exhibited inconsistent or minimal effects on AFP pain intensity. Adverse events were reported across multiple treatments, ranging from mild side effects such as dry mouth and nausea to severe reactions like diplopia and facial asymmetry, which impacted adherence. Despite some positive outcomes, the heterogeneity in study methodologies, outcome measures, and follow-up durations limited direct comparisons between interventions.

CONCLUSION:

This systematic review highlights the mixed efficacy of pharmacological treatments for AFP, with certain medications demonstrating superior pain relief in specific patient subgroups. Given the variability in response and adverse events, a multimodal approach combining pharmacological and non-pharmacological therapies may offer the most effective management strategy. Future research should focus on standardized treatment protocols, long-term efficacy, and personalized treatment plans to optimize patient care.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Diffusion characteristics and efficacy of letibotulinum toxin a in forehead wrinkle treatment

Article

作者: Nguyen, Ngoc Ha ; Lee, Young In ; Lee, Ju Hee ; Kim, Jemin ; Chau, Nam Hao ; Kim, Jihee ; Baek, Yujin

BACKGROUND:

Facial wrinkles, caused by aging and repetitive muscle contractions, are commonly treated with botulinum neurotoxin type A (BoNT-A). However, excessive toxin diffusion can cause side-effects like muscle weakness.

OBJECTIVES:

This study aimed to compare the diffusion, efficacy, and safety of letibotulinum toxin A with two other BoNT-A products for treating forehead wrinkles.

METHODS:

In a double-blind, randomized, split-face controlled trial, 20 participants with moderate-to-severe horizontal forehead wrinkles received letibotulinum toxin A on one side and prabotulinum or onabotulinum toxin A on the other. The primary outcome was diffusion profile assessed via anhidrosis area (iodine-starch test at 2 weeks); secondary outcomes included wrinkle reduction, assessed by photographic analysis, and safety.

RESULTS:

Results show that letibotulinum toxin A exhibited diffusion patterns and wrinkle-reduction efficacy comparable to the control products. No statistically significant differences were observed be-tween the groups for the primary or secondary outcomes.

CONCLUSION:

Letibotulinum toxin A is a safe, effective alternative for wrinkle treatment, potentially minimizing excessive diffusion risks and related side effects, making it a valuable addition to available treatment options.

2025-12-01·Techniques in Coloproctology

Management of chronic anal fissures: should fissurectomy be performed with botulinum toxin injection?

Article

作者: Albayati, S ; Ellis-Clark, J ; Quinn, R

Abstract:

Background:

Despite the superior success rate of lateral internal sphincterotomy for managing chronic anal fissure (CAF), there is a trend towards sphincter-preserving treatment due to the increased risk of incontinence. Botulinum toxin (BT) and fissurectomy are two sphincter-preserving options for CAF. We aim to assess if combining fissurectomy with botox treatment is superior to botulinum toxin alone in the management of CAF.

Methods:

This retrospective cohort study was conducted across two Sydney hospitals over 7 years. All patients with a CAF managed with either BT and fissurectomy (group 1) or BT only (group 2) were included. Primary outcome was healing rate defined as resolution or significant improvement of perianal symptoms at initial follow-up. Secondary outcomes were persistence, recurrence, re-intervention and faecal incontinence rate. Follow-up questionnaire was conducted to compare long-term outcomes between the two groups.

Results:

Fifty-seven patients met the inclusion criteria (group 1, 37; group 2, 20). Mean BT dose and injection location between the groups were similar (p = 0.259 and p = 0.427). There was a 65% response rate to the follow-up questionnaire. Median follow-up was 34.3 months (range 0.4–93). There was no difference in healing (56.7% vs. 50%, p = 0.561), recurrence (37.8% vs. 30%, p = 0.383) or re-intervention rate (13.5% vs. 20%, p = 0.888). Long-term incontinence rate was significantly higher in patients group 2 (0% vs. 10%, p = 0.010), with two patients reporting persistent flatus incontinence. Median overall satisfaction score was 3/4 (range 1–4), in both groups (p = 0.469).

Conclusion:

Botulinum toxin with or without fissurectomy is a safe sphincter-sparing treatment option for CAF. However, the addition of fissurectomy to BT does not improve healing rates and we therefore recommend BT injection alone as a second-line treatment of CAF in patients who fail topical treatment.

423

项与 A型肉毒毒素相关的新闻（医药）

2025-11-07

·LONGPORT

美股盘中速递：财报不佳叠加评级下调，Intellia 股价暴跌 20

Intellia 治疗跌 20.50%；吉利德科学跌 3.53%，成交额达到 1.96 亿美元；艾伯维跌 0.58%，成交额达到 1.68 亿美元；Natera 跌 3.70%，成交额达到 1.41 亿美元；安进涨 0.51%，市值达到 1708 亿美元。美股盘中速递Intellia 治疗跌 20.50%。基于近期关键新闻：1. 11 月 7 日，Intellia Therapeutics 公布第三季度财报，显示运营收入为-1.11 亿美元，合作收入为 1378.2 万美元，运营费用为 1.25 亿美元，基本每股收益为-0.92 美元。财报结果不佳导致股价下跌。2. 11 月 7 日，摩根大通将 Intellia 的股票评级从中性下调至减持，并将目标价从 12 美元下调至 5 美元。评级下调加剧了市场对该股的负面情绪。3. 11 月 7 日，Intellia 的治疗方案在临床试验中出现安全事件，导致市场对其未来发展持谨慎态度。公司尚未披露具体安全事件数量，增加了不确定性。生物科技行业近期面临监管挑战。行业成交额排名前列的股票吉利德科学跌 3.53%。基于近期关键新闻：1. 11 月 7 日，吉利德科学的乳腺癌药物 Trodelvy 未能在晚期研究中达到主要目标。该药物未能显著降低疾病进展风险，导致市场对其前景的担忧加剧，股价因此下跌。2. 11 月 7 日，美团医药健康在进博会上与吉利德科学等七家跨国企业达成战略合作。尽管合作有助于拓展市场，但未能抵消 Trodelvy 研究结果带来的负面影响。3. 11 月 6 日，吉利德科学计划在中国递交长效 HIV 药物 Lenacapavir 的上市申请。虽然此举显示出公司在中国市场的扩展计划，但短期内未能提振股价。医药行业政策支持创新药加速上市。艾伯维跌 0.58%。基于近期新闻，1. 11 月 4 日，艾伯维发布了第三季度财报，显示其美容产品 Botox Cosmetic 和 Juvederm Collection 销售强劲，分别实现了 637 百万美元和 253 百万美元的收入。然而，整体业绩受到美学板块挑战和 Humira 销售下降的影响，导致股价下跌。2. 11 月 4 日，艾伯维上调了 2025 年全年业绩预期，预计未来 12 个月内将有多个关键临床试验数据发布和产品审批，这些因素可能对未来市场表现产生影响，但短期内未能提振股价。3. 11 月 7 日，市场分析师认为艾伯维虽然有 “适度买入” 评级，但并未列入顶级分析师推荐的五只股票名单，这削弱了投资者信心，导致股价承压。宏观经济因素和行业趋势影响明显。Natera 跌 3.70%，成交量放大。基于近期关键新闻：1. 11 月 6 日，Natera 公布第三季度运营亏损为 9760 万美元，净亏损为 8750 万美元，导致市场对其盈利能力的担忧加剧，股价下跌。2. 11 月 4 日，Natera 执行主席 Matthew Rabinowitz 出售公司普通股，交易总额为 459 万美元，此举被市场解读为管理层对公司前景信心不足，进一步施压股价。3. 11 月 7 日，尽管 Natera 上调了 2025 年收入指引，但高额运营费用和净亏损仍然引发投资者对其财务健康的担忧，影响股价表现。医疗行业整体表现稳健，宏观经济数据支持增长。行业市值排名前列的股票安进涨 0.51%，成交量放大。基于近期关键新闻：1. 11 月 6 日，安进与外高桥集团签署战略合作协议，深化通关便利化及保税物流合作，巩固其在华发展基础，推动股价上涨。来源：金十数据2. 11 月 5 日，安进公布第三季度财报，每股收益 5.64 美元，高于市场预期，推动股价上涨。来源：安进公司公告3. 11 月 5 日，安进停止贝玛妥珠单抗的临床研究，因疗效不足，可能对股价产生负面影响。来源：经济通通讯社生物医药行业创新驱动，市场关注度高。美股盘中速递Intellia 治疗跌 20.50%。基于近期关键新闻：1. 11 月 7 日，Intellia Therapeutics 公布第三季度财报，显示运营收入为-1.11 亿美元，合作收入为 1378.2 万美元，运营费用为 1.25 亿美元，基本每股收益为-0.92 美元。财报结果不佳导致股价下跌。2. 11 月 7 日，摩根大通将 Intellia 的股票评级从中性下调至减持，并将目标价从 12 美元下调至 5 美元。评级下调加剧了市场对该股的负面情绪。3. 11 月 7 日，Intellia 的治疗方案在临床试验中出现安全事件，导致市场对其未来发展持谨慎态度。公司尚未披露具体安全事件数量，增加了不确定性。生物科技行业近期面临监管挑战。行业成交额排名前列的股票吉利德科学跌 3.53%。基于近期关键新闻：1. 11 月 7 日，吉利德科学的乳腺癌药物 Trodelvy 未能在晚期研究中达到主要目标。该药物未能显著降低疾病进展风险，导致市场对其前景的担忧加剧，股价因此下跌。2. 11 月 7 日，美团医药健康在进博会上与吉利德科学等七家跨国企业达成战略合作。尽管合作有助于拓展市场，但未能抵消 Trodelvy 研究结果带来的负面影响。3. 11 月 6 日，吉利德科学计划在中国递交长效 HIV 药物 Lenacapavir 的上市申请。虽然此举显示出公司在中国市场的扩展计划，但短期内未能提振股价。医药行业政策支持创新药加速上市。艾伯维跌 0.58%。基于近期新闻，1. 11 月 4 日，艾伯维发布了第三季度财报，显示其美容产品 Botox Cosmetic 和 Juvederm Collection 销售强劲，分别实现了 637 百万美元和 253 百万美元的收入。然而，整体业绩受到美学板块挑战和 Humira 销售下降的影响，导致股价下跌。2. 11 月 4 日，艾伯维上调了 2025 年全年业绩预期，预计未来 12 个月内将有多个关键临床试验数据发布和产品审批，这些因素可能对未来市场表现产生影响，但短期内未能提振股价。3. 11 月 7 日，市场分析师认为艾伯维虽然有 “适度买入” 评级，但并未列入顶级分析师推荐的五只股票名单，这削弱了投资者信心，导致股价承压。宏观经济因素和行业趋势影响明显。Natera 跌 3.70%，成交量放大。基于近期关键新闻：1. 11 月 6 日，Natera 公布第三季度运营亏损为 9760 万美元，净亏损为 8750 万美元，导致市场对其盈利能力的担忧加剧，股价下跌。2. 11 月 4 日，Natera 执行主席 Matthew Rabinowitz 出售公司普通股，交易总额为 459 万美元，此举被市场解读为管理层对公司前景信心不足，进一步施压股价。3. 11 月 7 日，尽管 Natera 上调了 2025 年收入指引，但高额运营费用和净亏损仍然引发投资者对其财务健康的担忧，影响股价表现。医疗行业整体表现稳健，宏观经济数据支持增长。行业市值排名前列的股票安进涨 0.51%，成交量放大。基于近期关键新闻：1. 11 月 6 日，安进与外高桥集团签署战略合作协议，深化通关便利化及保税物流合作，巩固其在华发展基础，推动股价上涨。来源：金十数据2. 11 月 5 日，安进公布第三季度财报，每股收益 5.64 美元，高于市场预期，推动股价上涨。来源：安进公司公告3. 11 月 5 日，安进停止贝玛妥珠单抗的临床研究，因疗效不足，可能对股价产生负面影响。来源：经济通通讯社生物医药行业创新驱动，市场关注度高。

财报临床研究

2025-11-03

·PRNewswire

Endeavor Health Acquires Diamond Headache Clinic

Acquisition strengthens Endeavor's leadership in neurosciences, expands access to nationally recognized headache and migraine care EVANSTON, Ill., Nov. 3, 2025 /PRNewswire/ -- Endeavor Health℠ today announced that it has acquired Diamond Headache Clinic to form the Endeavor Health Diamond Headache & Migraine Center. Diamond is a practice with more than 40 years of experience providing cutting-edge headache and migraine treatment to patients in Chicago, the Midwest and throughout the U.S. The acquisition advances Endeavor Health's strategic commitment to expanding its nationally ranked Neurosciences Institute¹, strengthens its capabilities in highly specialized care and positions it to deliver even more coordinated, innovative and accessible care to patients across the region and beyond. "Endeavor Health is proud to welcome Diamond Headache Clinic, a respected provider of headache and migraine care with a strong reputation regionally and nationally, into our healthcare system," said David Rahija, President, Endeavor Health Northwest Community Hospital and System Executive, Endeavor Health Neurosciences Institute. "This combination of Diamond's expertise and Endeavor's comprehensive resources reinforces Endeavor's commitment to providing world-class, expert care close to home for our communities." Diamond uses a comprehensive and multidisciplinary approach to tailor treatment plans for each patient. A team of physicians and specially trained APPs (advanced practice providers) offer a wide range of options, including acupuncture, biofeedback, Botox®, dietary guidance, infusions, injectable medications, massage therapy, nerve blocks, oral medications, physical therapy and psychological intervention. Diamond is also known as a leading research center with a history of pivotal studies that led to approval of many of the currently available treatments. Through its research department, Diamond continues to develop innovative therapies and approaches to the management of headaches and migraines. Diamond Headache was founded in 1974 by Dr. Seymour Diamond, who said he was able to count on one hand the number of physicians throughout the U.S. who were focused on doing "headache work." Dr. Diamond made it his mission to bring awareness across the world that headaches are a legitimate disease. "My dad respected and cared for a population of patients no one understood. He believed migraine was a disease and had great empathy and compassion. He was a great clinician and advocate for the headache patient," said Merle Diamond, MD. "I'm very excited about our partnership with Endeavor Health and the opportunity to continue my dad's legacy and advance the quality of care for our patients." The Endeavor Health Diamond Headache & Migraine Center has physician offices at 1460 N. Halsted St., Suite 501 in Chicago and 2150 Pfingsten Rd., Suite 2260 on the campus of Endeavor Health Glenbrook Hospital in Glenview. Patients requiring inpatient care will be seen by the expert team in newly renovated space at Northwest Community Hospital (NCH) in Arlington Heights. The state-of-the-art unit was designed specifically for Diamond Headache's dedicated inpatient headache program, one of only three in the U.S. and five in the world. The addition of Diamond to Endeavor Health is the latest development in the expansion of Endeavor Health's neurosciences services at NCH, including a dedicated Neuro Intensive Care Unit, stroke follow-up clinic, epilepsy monitoring unit and expanded sleep lab. For more information, visit or call 800-HEADACHE (800-432-3224). 1 U.S. News & World Report's 2025-26 Best Hospitals Rankings and Ratings: Endeavor Health℠ NorthShore Hospitals, which includes Evanston, Glenbrook, Highland Park and Skokie Hospitals, ranked #49 in the U.S. in Neurology & Neurosurgery. About Endeavor Health Endeavor Health℠ is a Chicagoland-based integrated health system driven by our mission to help everyone in our communities be their best. As Illinois' third-largest health system and third-largest medical group, we proudly serve an area of more than 4.1 million residents across seven northeast Illinois counties. Our more than 28,300 team members, including more than 1,900 employed physicians, are the heart of our organization, delivering seamless access to personalized, pioneering, world-class patient care across more than 300 ambulatory locations and nine hospitals, including eight Magnet-recognized acute care hospitals – Edward (Naperville), Elmhurst, Evanston, Glenbrook (Glenview), Highland Park, Northwest Community (Arlington Heights), Skokie and Swedish (Chicago) and Linden Oaks Behavioral Health Hospital (Naperville). For more information, visit . Contact: Keith Hartenberger (630) 527-3929 [email protected] SOURCE Endeavor Health 21% more press release views with Request a Demo

并购

2025-11-01

·生物制品圈

艾伯维三度上调 2025 营收预期，Skyrizi 与 Rinvoq 成增长引擎

摘要：艾伯维公司 2025 年第三季度业绩亮眼，连续三个季度上调全年营收预测，此次上调 4 亿美元后，预期营收达 609 亿美元，较年初预测高出 19 亿美元。这一增长主要得益于 Skyrizi 和 Rinvoq 两款免疫药物的强劲销售，同时公司神经科学领域产品也贡献力量，但 Humira 销售额大幅下滑，股价也出现小幅波动。营收预测三连涨，增长动力强劲 10 月 31 日，美国伊利诺伊州制药巨头艾伯维宣布，将 2025 年营收预测再次上调 4 亿美元，预计全年销售额达 609 亿美元。这是该公司今年以来第三次上调营收预期，较年初的预测高出 19 亿美元。艾伯维 CEO 罗布・迈克尔在周五的电话会议上表示：“很明显，增长势头正持续。2025 年每个季度，我们都超额完成目标并上调预期。” 财报显示，该公司第三季度总营收达 157.8 亿美元，同比增长 9%，比市场普遍预期高出 2 亿美元，进一步印证了其增长实力。明星药物表现突出，远超 Humira 巅峰期艾伯维的增长离不开两款免疫药物 Skyrizi 和 Rinvoq 的出色表现。据公司 CFO 斯科特・雷恩茨介绍，基于 Skyrizi 在银屑病和炎症性肠病领域的市场份额提升，公司将其 2025 年销售额预期上调 2 亿美元，至 173 亿美元。第三季度，Skyrizi 销售额达 47 亿美元，同比增长 47%；Rinvoq 销售额 22 亿美元，同比增长 35%。两款药物该季度合计销售额 69 亿美元，远超 Humira 在专利到期前的单季最高销售额 ——2022 年第四季度的 56 亿美元。市场竞争与挑战并存尽管表现强劲，艾伯维仍面临竞争压力。强生公司上月获得 FDA 批准，将其药物 Tremfya 用于溃疡性结肠炎治疗，这对 Skyrizi 构成挑战。不过，艾伯维首席商务官杰夫・斯图尔特认为，IL-23 类药物市场正快速扩张，并非零和博弈。斯图尔特透露，一年前 IL-23 类药物在溃疡性结肠炎治疗中的市场渗透率仅为 5%，如今已接近 40%。“这是 IL-23 类药物应用的巨大转变，而且艾伯维在该市场拥有 Skyrizi 和 Rinvoq 的双重优势。” 此外，艾伯维也面临一些挑战。本月初，公司因收购相关的在研项目费用和里程碑支出，面临 27 亿美元损失，导致市值受损。尽管第三季度业绩超预期，但截至午盘，公司股价仍下跌约 4%。其他业务板块喜忧参半在神经科学领域，艾伯维表现良好，将该板块全年销售额预期上调 2 亿美元，这一增长来自抗精神病药物 Vraylar、新型帕金森病药物 Vyalev 以及肉毒素 Botox 的治疗用途。与之相反，Botox 的美容用途销售额不及预期，公司将其全年销售额预期下调 2 亿美元。同时，曾创下年销售额超 200 亿美元的 “药王” Humira 持续下滑，第三季度销售额仅 9.93 亿美元，同比下降 55%，这是自 2007 年以来其季度销售额首次低于 10 亿美元。参考来源：https://www.fiercepharma.com/pharma/abbvie-boosts-revenue-forecast-again-thanks-booming-sales-skyrizi-rinvoq 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

财报免疫疗法专利到期并购

100 项与 A型肉毒毒素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08957	A型肉毒毒素	M03AX01	DB00083

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
咀嚼肌肥大	中国	Allergan, Inc.	2024-06-03
肌张力失调	美国	AbbVie, Inc.	2022-08-22
神经源性逼尿肌过度活动	美国	AbbVie, Inc.	2022-08-22
发声困难	日本	GSK Plc	2018-05-25
膀胱功能障碍	美国	AbbVie, Inc.	2017-04-04
外眦皱纹	美国	AbbVie, Inc.	2013-09-11
上下肢痉挛	美国	AbbVie, Inc.	2010-03-09
马蹄状畸形	日本	Allergan, Inc.	2009-01-21
多汗症	日本	Allergan, Inc.	2009-01-21
皮肤疾病	日本	Allergan, Inc.	2009-01-21
神经性膀胱功能障碍	日本	Allergan, Inc.	2009-01-21
原发性颈性肌张力障碍	日本	GSK Plc	2005-10-03
肌肉痉挛	-	Genesis Healthcare, Inc.	2005-10-03
肌痛性痉挛	中国	Allergan Pharmaceuticals Ireland ULC	2003-04-22
斜颈	日本	GSK Plc	2000-06-20
马蹄足	日本	GSK Plc	2000-02-23
面肌痉挛	日本	GSK Plc	2000-01-18
眼睑痉挛	澳大利亚	AbbVie Pty Ltd.	1999-07-09
颈肌张力障碍	澳大利亚	AbbVie Pty Ltd.	1999-07-09
鱼尾纹	澳大利亚	AbbVie Pty Ltd.	1999-07-09

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先兆偏头痛	临床3期	美国	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	加拿大	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	捷克	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	德国	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	以色列	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	波兰	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	西班牙	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	瑞典	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	英国	AbbVie, Inc.	2021-11-05
无先兆偏头痛	临床3期	美国	AbbVie, Inc.	2021-11-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05100199 (CTgov)	临床2期	眉间纹	328	Placebo (Placebo)	願鹹鹽範製繭夢顧範築 = 鹽築簾鏇鑰鬱壓夢廠蓋餘夢願糧蓋鑰衊獵廠遞 (壓鏇廠觸淵糧糧糧選網, 範鏇廠淵鹹製簾網廠艱 ~ 窪觸鑰衊衊鏇膚構繭衊) 更多	-	2025-09-09
NCT05100199 (CTgov)	临床2期	眉间纹	328	OnabotulinumtoxinA X (OnabotulinumtoxinA X Dose A)	願鹹鹽範製繭夢顧範築 = 觸襯壓願窪製鑰憲窪簾餘夢願糧蓋鑰衊獵廠遞 (壓鏇廠觸淵糧糧糧選網, 壓壓壓鑰憲繭築鹽醖構 ~ 淵餘獵鹹膚願齋蓋積壓) 更多	-	2025-09-09
NCT06218251 (UFL BOND 974, CTgov)	临床4期	面部皱纹	100	BOTOX	積積選襯網製壓顧築鏇 = 醖憲觸夢醖醖夢觸顧夢願艱壓夢遞觸衊蓋醖鏇 (鑰願積憲鹹鏇鹽鹽醖艱, 餘顧觸獵製願蓋遞廠願 ~ 範網淵製憲願選願積蓋) 更多	-	2025-08-06
NCT04609020 (CTgov)	临床4期	皮肤疾病 \| 皮肤起皱	64	Lidocaine+BOTOX	齋遞築醖衊鬱鬱衊艱餘(齋鏇鑰鏇膚艱淵壓鑰蓋) = 壓憲獵壓衊襯廠蓋繭顧齋構鑰鏇廠糧構壓膚築 (製鬱鏇餘膚積繭觸鏇餘, 23.61) 更多	-	2025-06-17
NCT04965311 (CTgov)	临床2期	胰腺瘘 \| 胰腺癌	4	Botulinum Toxin Type A	鬱鑰廠壓簾鹽糧襯製齋 = 膚製鏇繭淵觸簾醖憲獵壓齋網壓蓋鏇網願襯繭 (觸築廠構願憲窪選選襯, 鑰窪夢壓夢齋餘襯顧顧 ~ 鬱齋繭窪鏇築鏇選蓋餘) 更多	-	2025-05-13
NCT01686581 (REPOSE, Pubmed \| BMC Neurol)	临床3期	偏头痛	641	155 U onabotulinumtoxinA	觸蓋窪衊築鏇獵鏇製壓(鑰廠網繭餘觸繭獵鏇願) = Adverse drug reactions (ADR) were reported in 51/218 in the 155 U group and 10/77 participants in the 156 U - 195 U group; serious adverse drug reactions were 3/218 and 1/77, respectively. The most frequently reported ADR across both dose groups was eyelid ptosis, followed by neck pain, musculoskeletal stiffness 壓顧廠鏇鹹鹽鬱顧膚鹹 (衊壓積鑰膚範衊範蓋簾 ) 更多	积极	2025-05-06
NCT01686581 (REPOSE, Pubmed \| BMC Neurol)	临床3期	偏头痛	641	156 U - 195 U onabotulinumtoxinA		积极	2025-05-06
NCT04073303 (CTgov)	临床3期	-	377	Placebo	遞壓醖鬱鑰鬱遞顧鏇願 = 艱築鬱顧簾艱築簾壓壓艱鏇淵遞鹹襯淵構餘鹹 (廠製壓襯糧壓繭積鏇夢, 憲淵範繭積鹹憲膚繭範 ~ 艱淵築鹹淵壓壓餘繭製) 更多	-	2025-05-06
AAN2025	N/A	偏头痛 \| 颈肌张力障碍	279	OnabotulinumtoxinA	衊衊糧襯齋積憲蓋顧鏇(糧簾構鑰餘鬱壓構鹽艱) = UTI (range 0.7-5.7%) 壓窪簾醖製構顧衊夢鬱 (鏇鹽鹽衊遞窪願遞餘構 ) 更多	积极	2025-04-07
NCT04171531 (MUSA, CTgov)	临床3期	压力性尿失禁 \| 急迫性尿失禁	150	Mid-urethral sling	獵願鹽窪夢壓製顧鬱構(夢願夢遞構壓膚繭願製) = 膚積構膚簾繭膚願簾膚襯廠鑰淵醖簾繭構齋築 (構蓋膚夢膚膚衊觸鑰簾, 鑰憲夢鹽鹽憲鏇憲壓襯 ~ 壓網構積鏇淵廠齋壓糧) 更多	-	2025-03-20
NCT05308979 (CTgov)	临床4期	尿频 \| 急迫性尿失禁 \| 膀胱过度活动症综合征	116	OnabotulinumtoxinA 100 UNT [Botox] (1 Injection Site)	憲顧鑰夢蓋鑰憲簾鹹糧(餘艱鬱繭艱鹽繭選夢構) = 淵觸顧鏇鏇遞選蓋鬱積夢鑰遞製襯構淵廠製窪 (淵蓋襯齋壓積齋範鹽鹹, 26.25) 更多	-	2025-02-14
NCT05308979 (CTgov)	临床4期	尿频 \| 急迫性尿失禁 \| 膀胱过度活动症综合征	116	OnabotulinumtoxinA 100 UNT [Botox] (10 Injection Sites)	憲顧鑰夢蓋鑰憲簾鹹糧(餘艱鬱繭艱鹽繭選夢構) = 廠鑰鏇獵鑰鬱觸繭餘網夢鑰遞製襯構淵廠製窪 (淵蓋襯齋壓積齋範鹽鹹, 24.92) 更多	-	2025-02-14
NCT05134649 (CTgov)	临床3期	颈阔肌突出	292	OnabotulinumtoxinA	襯壓憲齋醖顧衊鬱鑰築(獵糧膚鏇鬱遞願鏇餘鬱) = 觸膚製選範齋鑰鹹廠夢窪膚鹽餘鏇齋襯顧積憲 (蓋糧鏇憲顧衊選鹹構獵, 夢製獵艱淵繭構鏇簾淵 ~ 膚鹹夢構膚網網醖夢鬱) 更多	-	2024-12-05